Roche (RHHBY) has announced a significant investment plan, committing $50 billion over the next five years to bolster its presence in the United States. This expansion strategy will enhance Roche's existing infrastructure, which currently comprises 13 manufacturing and 15 research and development (R&D) sites within its Pharmaceutical and Diagnostics Divisions. As part of this substantial investment, Roche aims to generate more than 12,000 new jobs, including 6,500 construction-related positions and an additional 1,000 roles at new and expanded facilities.
The investment will see Roche augment its workforce of over 25,000 employees spread across 24 sites in eight states. Key initiatives include boosting manufacturing and distribution capacity for innovative medicines and diagnostics in Kentucky, Indiana, New Jersey, Oregon, and California. Additionally, Roche will establish a cutting-edge gene therapy manufacturing facility in Pennsylvania and construct a 900,000 square foot manufacturing center dedicated to next-generation weight loss medications.
In Indiana, a new facility for continuous glucose monitoring will be developed, while Massachusetts will host a new R&D center focused on artificial intelligence and research in cardiovascular, renal, and metabolism fields. Furthermore, Roche plans significant upgrades and expansions at existing R&D centers in Arizona, Indiana, and California. This investment underscores Roche's commitment to innovation and growth, leveraging its strong heritage and footprint in the US to support jobs, research, and intellectual property creation.
